IP Verse

Camulon competitive analysis

Explore patent oppositions filed by Camulon against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 9, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3411021	New Use Of A Combination Of Sacubitril And Valsartan	NOVARTIS	Sep 1, 2025
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 21, 2025
EP3570885	Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)	AMGEN	Jun 17, 2025
EP3697917	Vector For The Production Of Aav Particles	OXFORD GENETICS	Feb 14, 2025
EP3953262	Thin Wall Container Made With A Recycled Material	SOCIT ANONYME DES EAUX MINRALES DEVIAN ET EN ABRG SAEME	Dec 6, 2024
EP2395968	Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient	BOEHRINGER INGELHEIM	Oct 14, 2024
EP3626270	New Use	NOVARTIS	Jul 10, 2024
EP3042669	Antitumor Agent And Antitumor Effect Enhancer	TAIHO PHARMACEUTICAL	Nov 29, 2023
EP3294283	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Nov 23, 2023
EP3883606	Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody	JANSSEN BIOTECH	Jul 27, 2023

Explore the latest publications and patents granted to Camulon, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Camulon, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Camulon with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
CAMULON	12	-	-	-
APTALIS PHARMA	-	4	-	-
ARZUFFI	-	1	-	-
NOVARTIS	6	422	-	21